Delivery Order SPE2DB20D3101-SPE2DB25FRPG6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $8,109.88. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $1,722.87. This firm fixed-price delivery order, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) with a ceiling value of $19,958.40 under a firm fixed-price contract type. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and represents a non-set-aside competitive award. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) with a ceiling value of $40,767.56. This firm fixed-price delivery order, which must be completed by June 9, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $7,437.20 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.33 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used to treat overactive bladder symptoms,...
- The Defense Logistics Agency awarded a $27,931.77 firm fixed price delivery order to AmerisourceBergen Drug Corp for 90-count bottles of Gemtesa 75 mg tablets, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award was issued on August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription medication used to treat overactive bladder, representing one component of the pharmaceutical...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRPG6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count packaging) under a firm fixed-price contract valued at $2,679.22. The award, issued on July 3, 2025, with an ultimate completion date of July 7, 2025, represents a non-competitive procurement leveraging the company's existing contract vehicle. Performance of this delivery order will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to military healthcare programs worldwide. Gemtesa, a medication used in the treatment of overactive bladder, represents one of many specialized pharmaceutical products the company delivers through this framework to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 7/3/25 |